DSIP is a nine-amino-acid peptide investigated for sleep-related effects. Some small human studies reported improvement, while other controlled studies found little meaningful benefit. The name “delta sleep-inducing peptide” does not establish that it reliably increases deep sleep.
Also called emideltide, DSIP has a much longer research history than many online summaries suggest. The useful question is what changed in each experiment: time asleep, time spent awake, a sleep-stage recording or simply how someone felt.
What is DSIP, and where did the name come from?
The original researchers isolated a sleep-associated peptide from the dialysate of cerebral venous blood in rabbits undergoing electrical stimulation. They then synthesized the sequence and compared it with related peptides. The 1977 report described enhanced delta and spindle EEG patterns after administration into the brain. That is a specific rabbit experiment, not evidence that a retail preparation will reproduce a person’s deep sleep. Schoenenberger and Monnier, 1977
Trp–Ala–Gly–Gly–Asp–Ala–Ser–Gly–Glu
Letters identify amino acids, not separate benefits. This is a sequence diagram, not a measured three-dimensional structure.
The follow-up chemical study distinguished the ordinary alpha-aspartyl sequence from its beta-aspartyl isomer: only the former showed high activity in that assay. Even a preparation with the same amino-acid inventory may therefore differ in its linkage and behavior. Schoenenberger and colleagues, 1978
PubChem CID 68816 gives the peptide reference formula as C35H48N10O15, approximately 848.8 g/mol. A salt, modified analogue or fusion construct needs its own identity and mass basis. FDA’s current assessment likewise distinguishes emideltide free base from emideltide acetate; the shared name does not make those preparations interchangeable.
Does DSIP actually work for sleep?
There are human studies, but they do not establish a reliable treatment effect. Much of the direct insomnia evidence comes from small studies in the 1980s and 1990s, with differing controls and short observation periods. A favorable result should remain visible alongside a weak or conflicting result.
Sleep-onset latency
How long it takes to fall asleep. A shorter delay does not, by itself, show more deep sleep.
Sleep efficiency
The proportion of the recording or time in bed spent asleep. The denominator matters.
Slow-wave sleep
A stage measured through sleep recordings. It is different from feeling rested or spending more time in stage 2.
These are definitions of measurements, not a patient sleep trace or results from a simulated night.
Six healthy volunteers: a short observation window
In a double-blind crossover experiment, median total sleep time within a 130-minute interval was 59% higher after DSIP than placebo. This was six healthy volunteers and a particular laboratory window—not 59% more deep sleep overnight, or a predicted improvement for people with insomnia. Schneider-Helmert and colleagues, 1981
Six people with chronic insomnia: a positive early signal
A separate study reported longer, less interrupted sleep. It also described a slight arousing effect in the first hour, with sleep-promoting effects later. The small crossover design and possible carryover between consecutive nights complicate interpretation. This does not establish one universal onset time. Schneider-Helmert and Schoenenberger, 1981
Seven patients: promising follow-up without a blinded comparator
An open study reported normalized sleep in six of seven patients during follow-up lasting three to seven months. That is an interesting observation. Without a parallel blinded comparison, it cannot isolate the peptide’s contribution or establish how long an individual response should last. Kaeser, 1984
Positive findings and a separate weak-effect study
A 14-person study reported improvements in sleep and daytime performance. A separate double-blind crossover study found little clinical benefit: apparent differences in stage 2 and non-REM sleep were already present at baseline, while slow-wave and REM sleep did not change. The second report does not support the assumption that DSIP always increases deep sleep. Schneider-Helmert, 1987; Monti and colleagues, 1987
Sixteen people, with eight in each group
Five laboratory nights included adaptation and baseline recordings followed by three treatment nights.
DSIP
Placebo
Why do different summaries reach different conclusions?
They often treat unlike comparisons as equivalent. In the positive 14-person study, FDA’s review identified comparisons with the patients’ own baseline and an external group of healthy sleepers. That is different from comparing two groups with insomnia during the same treatment period. The original abstract called the study placebo-controlled; the actual control arrangement needs the extra explanation. FDA’s clinical review, pages 26–27
After treatment versus before
Sleep can improve as someone adapts to a laboratory, as symptoms fluctuate or as expectations change. The improvement is a real observation; its cause still needs testing.
DSIP versus placebo
A suitable concurrent control helps distinguish those influences. Small samples, baseline imbalance and multiple outcomes can still make the result uncertain.
As of September 8, 2026, separate ClinicalTrials.gov searches for DSIP, emideltide and the expanded peptide name returned no records. That dated registry result does not erase the older published human studies. Conversely, several papers or a multi-study summary should not automatically be counted as several independent modern confirmations.
Does DSIP increase testosterone or growth hormone—or lower cortisol?
The available experiments do not support those claims as general human effects. A rat study found increased luteinizing hormone after administration into the brain, with related experiments involving hypothalamic tissue. It did not demonstrate increased testosterone in men. Iyer and colleagues, 1987
A study of eight healthy women found no effect on measured growth-hormone or prolactin secretion under its tested conditions. That includes an important null result; animal endocrine pathways should not replace it. Giusti and colleagues, 1993
The stress-hormone findings also differ. In an 11-man crossover study, ACTH-like immunoreactivity decreased but cortisol did not. Later experiments found that DSIP did not alter ACTH or cortisol responses to CRH stimulation or a meal. “Affects a stress-related signal” is therefore more specific than “lowers cortisol.” Bjartell and colleagues, 1989; Späth-Schwalbe and colleagues, 1995
Is DSIP a natural sleep hormone with a known receptor?
The original sequence is defined, but a simple natural-hormone story goes beyond the evidence. Antibody recognition is one reason for caution: researchers isolated a 77-residue peptide from pig brain that reacted with an antibody against DSIP even though its amino-acid sequence was unrelated. A signal called “DSIP-like immunoreactivity” is not automatically proof of the nine-residue molecule. Sillard and colleagues, 1993
A later sequence-search study proposed a related peptide, KND, within a histone-demethylase protein. KND differs from DSIP at two positions. The authors presented a possible source of DSIP-like activity, not a demonstrated biosynthetic pathway for the exact DSIP sequence. Mikhaleva and colleagues, 2011
Rat-neuron experiments reported modulation of GABA-activated currents and NMDA-related responses. These are mechanistic observations in a particular system; they do not establish DSIP as a selective human sleep-receptor drug, or show clinical equivalence to melatonin or a sedative. Grigor’ev and colleagues, 2006
What has newer DSIP research actually added?
Recent work asks broader questions about experimental delivery and neurological injury. Keep the exact molecule and endpoint beside the finding.
On a small screen, scroll the comparison table sideways to read all three columns.
| Material and study | What was observed | What remains separate |
|---|---|---|
| DSIP, 2021 rat stroke model | Motor coordination on a rotating rod recovered faster; the difference in brain infarct volume was not statistically significant. Tukhovskaya and colleagues | The experiment included treatment before the induced injury and afterward. It was not a trial of recovery, sleep or stroke treatment in people. |
| KND, a related sequence | A separate study reported smaller injury measures in animal reperfusion models. Its preliminary occlusion experiments also reported severe adverse outcomes. Tukhovskaya and colleagues, 2021 | The positive KND findings are not interchangeable with exact DSIP. Effects depended on the model and experimental timing; no human treatment inference follows. |
| DSIP fused to a delivery construct, 2024 | In a chemically induced mouse model, the authors measured behavior and neurotransmitter-related markers, comparing the fusion with other preparations. Mu and colleagues, 2024 | Locomotion, maze behavior and biochemical markers do not themselves measure human sleep stages. The fusion construct is not an ordinary nine-residue DSIP product. |
How long does DSIP take to work, and what is its half-life?
There is no dependable personal sleep-onset or duration prediction from these studies. An early experiment described a slight initial arousing effect before later sleep changes; another assessed a brief morning observation window. Neither tells a reader when a different preparation will make them sleep.
Peptide breakdown is a separate measurement. Laboratory work found degradation in human and rat blood, with rates depending on conditions; modified analogues behaved differently. A short-lived blood signal and a later sleep observation do not measure the same process. Graf and colleagues, 1987
Blood–brain barrier research also needs its model attached: a perfused guinea-pig brain experiment studied radiolabeled material and a saturable uptake mechanism. It did not establish a human nasal or subcutaneous bioavailability value. There is no basis here for turning those findings into a product-use interval. Zlokovic and colleagues, 1989
What are the side effects and safety gaps?
Some small sleep studies reported favorable short-term tolerability. Other settings produced relevant adverse observations. In a randomized study involving 24 women undergoing anesthesia, DSIP increased heart rate and reduced measures of anesthetic depth under some conditions; delta activity decreased rather than uniformly increasing. This was an anesthesia experiment, not ordinary sleep, but it argues against assuming a universally calming effect. Pomfrett and colleagues, 2009
Favorable small studies do not establish long-term safety
FDA’s 2026 review describes headaches, nausea, vertigo and cases of hypotension in a historical withdrawal-treatment series. Underlying withdrawal and uncertainty about some preparations complicate attribution. The same review found no clinical safety evidence for the nominated subcutaneous route. These are specific gaps, not a measured incidence of harm for every DSIP product.
FDA human safety assessment, pages 50–52. The agency’s search reporting zero adverse-event database records ended in March 2024; zero reports is not proof that no adverse events occurred.
Claims of no dependence, no interactions or suitability for everyone are not established by this record. Experimental work connected to opioid pathways and early withdrawal studies does not supply a validated detoxification method. DSIP should not be treated as a substitute for established care for a sleep disorder or withdrawal.
Is DSIP FDA approved?
DSIP is not an FDA-approved medicine. The FDA briefing prepared for the July 2026 advisory meeting evaluated emideltide free base and acetate and recommended against their inclusion on the 503A bulks list. That document is an agency assessment for an advisory process, not a drug approval or a final committee decision. The current FDA safety page lists emideltide among substances whose nominations were withdrawn and flags information gaps and potential immunogenicity concerns.
A research-use label, a compound name and a clinical formulation are different things. A laboratory report can describe a tested sample; it cannot establish that a preparation is approved or effective for insomnia.
What should a researcher verify about a DSIP material?
Check the exact sequence, linkage and specified preparation, then read the applicable sample report. Chromatographic peak-area percentage, identity analysis and measured content answer different questions. None alone establishes human benefit, an unlinked shipment’s identity or sterility unless tested.
The DSIP research-material page shows current configurations and availability. Use the Lab Verified library and COA reading guide to interpret the results. The neuroscience research overview places DSIP alongside compounds with different structures and research histories.
For laboratory research only. Not for human or veterinary use. This educational guide does not provide dosing, injection, reconstitution or combination instructions.
Frequently Asked Questions
What is DSIP?
DSIP means delta sleep-inducing peptide. It is a nine-residue peptide, also called emideltide, investigated for sleep-related and other experimental effects. Its defined sequence is WAGGDASGE. A salt, modified analogue or fusion construct is not automatically the same preparation.
Does DSIP actually work for sleep?
Small human studies reported inconsistent results. Some found better sleep, while other controlled studies found weak changes or little clinical benefit. The available record does not establish a reliable insomnia treatment or predict how an individual will respond.
Does DSIP increase deep sleep?
The name does not prove that effect. In one controlled human insomnia study, apparent changes concerned stage 2 rather than slow-wave sleep, and some differences already existed at baseline. Sleep efficiency, total sleep time and deep-sleep stages are different measurements.
How long does DSIP take to kick in?
There is no validated personal onset time from the studies reviewed here. An early six-person experiment described slight initial arousal followed by later sleep changes. Different study designs, preparations and endpoints cannot be combined into a guaranteed timing prediction.
Does DSIP increase testosterone or growth hormone?
The cited rat luteinizing-hormone finding is not evidence of increased testosterone in men. A small study in healthy women found no effect on measured growth-hormone or prolactin secretion. These experiments do not establish DSIP as a reliable human hormone-boosting treatment.
Does DSIP lower cortisol?
Not consistently in the human experiments reviewed. One study found reduced ACTH-like immunoreactivity without a cortisol change; later experiments found no effect on CRH- or meal-related ACTH and cortisol responses. A change in one stress-related signal is not a general cortisol-lowering effect.
What are the possible side effects of DSIP?
Small sleep studies reported favorable short-term tolerability, but other clinical settings included headaches, nausea, vertigo, hypotension and changes in heart rate. Context and preparation complicate interpretation. Long-term safety and safety for an unstudied route or retail formulation are not established.
Is DSIP the same as melatonin?
No. DSIP is a peptide; melatonin is a different molecule with a different evidence base. Changes in melatonin-related markers in animals do not make the compounds interchangeable or demonstrate that DSIP produces the same effects in people.
Is a DSIP nasal spray equivalent to the material in the sleep trials?
The direct human insomnia studies discussed here used intravenous preparations. A product described as a nasal spray, an oral product or a subcutaneous preparation cannot inherit their results without evidence for its own composition, delivery and use. The guide does not supply a personal administration protocol.
Is DSIP FDA approved?
DSIP is not an FDA-approved medicine. The 2026 FDA briefing assessed emideltide free base and acetate and recommended against adding them to the 503A bulks list. An advisory-process assessment is separate from drug approval. FDA also identifies safety-information gaps for emideltide.
Primary research and regulatory sources
The older human studies and newer animal work are presented separately. Scientific records and the dated regulatory materials were checked on September 8, 2026.
- Mu X et al. Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models. Frontiers in pharmacology. 2024. PMID 39444618.
- Tukhovskaya EA et al. Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke. Molecules (Basel, Switzerland). 2021. PMID 34500605.
- Tukhovskaya EA et al. DSIP-Like KND Peptide Reduces Brain Infarction in C57Bl/6 and Reduces Myocardial Infarction in SD Rats When Administered during Reperfusion. Biomedicines. 2021. PMID 33918965.
- Mikhaleva II et al. JmjC-domain-containing histone demethylases of the JMJD1B type as putative precursors of endogenous DSIP. Peptides. 2011. PMID 21262293.
- Pomfrett CJ et al. Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia. European journal of anaesthesiology. 2009. PMID 19142086.
- Grigor'ev VV et al. Effects of delta sleep-inducing peptide on pre- and postsynaptic glutamate and postsynaptic GABA receptors in neurons of the cortex, hippocampus, and cerebellum in rats. Bulletin of experimental biology and medicine. 2006. PMID 17369935.
- Späth-Schwalbe E et al. Delta-sleep-inducing peptide does not affect CRH and meal-induced ACTH and cortisol secretion. Psychoneuroendocrinology. 1995. PMID 7777652.
- Sillard R et al. A novel 77-residue peptide from porcine brain contains a leucine-zipper motif and is recognized by an antiserum to delta-sleep-inducing peptide. European journal of biochemistry. 1993. PMID 8375381.
- Giusti M et al. Delta sleep-inducing peptide administration does not influence growth hormone and prolactin secretion in normal women. Psychoneuroendocrinology. 1993. PMID 8475226.
- Bes F et al. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology. 1992. PMID 1299794.
- Zlokovic BV et al. Saturable mechanism for delta sleep-inducing peptide (DSIP) at the blood-brain barrier of the vascularly perfused guinea pig brain. Peptides. 1989. PMID 2547200.
- Bjartell A et al. Reduction of immunoreactive ACTH in plasma following intravenous injection of delta sleep-inducing peptide in man. Psychoneuroendocrinology. 1989. PMID 2554357.
- Iyer KS et al. Delta sleep inducing peptide (DSIP) stimulates the release of LH but not FSH via a hypothalamic site of action in the rat. Brain research bulletin. 1987. PMID 3121137.
- Graf MV et al. Degradation and aggregation of delta sleep-inducing peptide (DSIP) and two analogs in plasma and serum. Peptides. 1987. PMID 3628078.
- Schneider-Helmert D et al. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. European neurology. 1987. PMID 3622582.
- Monti JM et al. Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. International journal of clinical pharmacology research. 1987. PMID 3583493.
- Kaeser HE et al. A clinical trial with DSIP. European neurology. 1984. PMID 6391926.
- Schneider-Helmert D et al. Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. International journal of clinical pharmacology, therapy, and toxicology. 1981. PMID 6895513.
- Schneider-Helmert D et al. The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep. Experientia. 1981. PMID 7028502.
- Schoenenberger GA et al. The delta EEG (sleep)-inducing peptide (DSIP). XI. Amino-acid analysis, sequence, synthesis and activity of the nonapeptide. Pflugers Archiv : European journal of physiology. 1978. PMID 568769.
- Schoenenberger GA et al. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proceedings of the National Academy of Sciences of the United States of America. 1977. PMID 265572.
